Home >  News >  Industry >  Pharma News >  Union Health Minister...

Union Health Minister urges stakeholders to work towards building trust in Indian drugs, medical devices quality

The chintan shivir is being organised by the Union Ministry of Health and Family Welfare (MoHFW), in collaboration with the Department of Pharmaceuticals (DoP).;

By - Ruchika Sharma
Published On 2023-02-27 08:00 GMT   |   Update On 2023-02-27 08:01 GMT
Advertisement

New Delhi: Union Health Minister Mansukh Mandaviya urged all the stakeholders on Sunday to steadfastly work towards building trust and confidence in the quality of Indian drugs, cosmetics and medical devices in domestic and export markets.

It is of critical importance to ensure that the country's regulatory mechanisms are of impeccable standards that are sustained over time and space, Mandaviya said as he inaugurated a two-day "chintan shivir" on "Drugs: Quality Regulations and Enforcement" in Hyderabad.

"How can we ensure that the confidence of the consumers of pharmaceuticals manufactured in India is upheld? I urge all the stakeholders to steadfastly work towards making the Indian drugs regulatory system among the best in the world, which could be emulated by other countries," he said.
In his inaugural address, Mandaviya underlined the focus of the deliberative forum, saying, "The chintan shivir is a platform for all the stakeholders in the pharma and health sectors to deliberate on pathways for cohesive and synergistic approaches for building robust and resilient regulatory systems."
Advertisement
Various agencies across the Centre and states form important components to ensure that the pharmaceuticals manufactured in the country and consumed by domestic and international consumers are of the highest quality and adhere to the standard global manufacturing protocols, the minister said.
This will ensure that India's fame as the "pharmacy of the world" is upheld and the country provides pharma products of the highest quality to the consumers, he added.
The health minister highlighted that "it is of critical importance to ensure that the regulatory mechanisms of the country are of impeccable standards, which are sustained over time and space. This is possible when the central ministries and state bodies work in a spirit of cooperative federalism, building on the strengths of one another and working jointly to remove loopholes in the regulatory systems".
He encouraged the participants to share their knowledge and insights from their field-level experience to enrich the discussions over the two days of collaborative brainstorming.
"The challenges we face can be collaboratively addressed by pooling our collective experience. The manthan at the end of these two days will provide rich knowledge to build strong, sturdy, resilient and people-friendly mechanisms," Mandaviya said.
The chintan shivir is being organised by the Union Ministry of Health and Family Welfare (MoHFW), in collaboration with the Department of Pharmaceuticals (DoP).
The event brought together all the stakeholders -- the MoHFW, the DoP, health secretaries and drug controllers from the states and Union territories, industry associations -- on a common platform.
The participants at the conclave will brainstorm on various facets of producing a sturdy and resilient regulatory system for drugs, cosmetics and medical devices.
These include sessions on building trust and confidence in the quality of drugs in the domestic and global market, review predictability, transparency and accountability in the regulation of the quality of drugs, effective enforcement of quality, safety and efficacy at the field level, ensuring compliance to Indian pharmacopeia standards.
There will be sessions on developing a robust network for pharmacovigilance and materiovigilance programmes, creating a unified IT platform for all regulatory activities, to assess the regulatory capacity across the states and the Centre, along with promoting "ease of doing business" and capacity building at the level of the states and national regulators for the regulation of pharmaceuticals and medical devices.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Sun Pharma Agrees To Rs 1,654 Cr Settlement In U.S. Pricing Row

No Special Price for Novel Pack: NPPA Panel Turns Down Sun Pharma's Amoxicillin-Clavulanic Formulation

CDSCO Panel Seeks Safety Data on 5% Lenalidomide TDS Before Clearing 8% Patch Trial

Dr Reddy's Labs plans to roll out cheaper Wegovy copycat across 87 countries in 2026: CEO

Action taken against 694 manufacturing units since 2022: Minister

J&J Imbruvica gains EU approval for untreated Mantle Cell Lymphoma in transplant eligible patients

Shilpa Medicare arm to infuse USD 2 million in Alveolus Bio

NPPA Panel Rejects Dr Reddy's Omez ODT Plea For Seperate Price, Finds No Therapeutic Edge